Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma

New England Journal of Medicine

Volumn 322, Issue 1, 1990, Pages 16-21

  Badaro, Roberto ^a,c   Falcoff, Ernesto ^b   Badaro, Fernando S ^a   Carvalho, Edgar M ^a   Pedral Sampaio, Diana ^a   Barral, Aldina ^a   Carvalho, Jose S ^a   Barral Netto, Manoel ^a   Brandely, Maud ^d   Silva, Luciana ^a   Bina, Jose C ^a   Teixeira, Rodolfo ^a   Falcoff, Rebeca ^b   Rocha, Heonir ^a   ho, John L ^c   Johnson, Warren D ^c  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b INSTITUT CURIE   (France)

^c Department of Obstetrics Gynecology   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MEGLUMINE ANTIMONATE; RECOMBINANT GAMMA INTERFERON;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTOZOON; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANTIMONY; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON-GAMMA, RECOMBINANT; LEISHMANIASIS, VISCERAL; MALE;

EID: 0025139949     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199001043220104     Document Type: Article

References (33)

1. Marsden PD, Jones TC Clinical manifestations, diagnosis and treatment of leishmaniasis. In: Chang K-P, Bray RS, eds. Leishmaniasis. Vol. 1 of Ruitenberg EJ, Maclnnis AJ, eds. Human parasitic diseases. Amsterdam: Elsevier, 1985:183–98.
2. Marsden PD. Selective primary health care: strategies for control of disease in the developing world. XIV. Leishmaniasis. Rev Infect Dis 1984; 6: 736–44.
3. Eickhoff TC, Young LS. Gaps in therapy for infectious disease: conference summary. J Infect Dis 1982; 145: 407–12.
4. Bryceson AD, Chulay JD, Mugambi M, et al. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans Soc Trop Med Hyg 1985; 79: 705–14.
5. Carvalho EM, Teixeira RS, Johnson WD Jr. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 1981; 33: 498–500.
6. Ho M, Koech DK, Iha DW, Bryceson ADM. Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol 1983; 51: 207–14.
7. Carvalho EM, Badaró R, Reed SG, Jones TC, Johnson WD Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985; 76: 2066–9.
8. Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WD Jr. antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest 1989; 83: 860–4.
9. Crawford GD, Wyler DJ, Dinarello CA. Parasite-monocyte interactions in human leishmaniasis: production of interleukin-1 in vitro. J Infect Dis 1985; 152: 315–22.
10. Reiner NE. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani. J Immunol 1987; 138: 1919–25.
11. Reiner NE, Ng W, McMaster WR. Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. J Immunol 1987; 138: 1926–32.
12. Reiner NE, Malemud CJ. Arachidonic acid metabolism by murine peritoneal macrophages infected with Leishmania donovani: in vitro evidence for parasite-induced alterations in cyclooxygenase and lipoxygenase pathways. J Immunol 1985; 134: 556–63.
13. Reiner NE, Ng W, Ma T, McMaster WR. Kinetics of γ-interferon binding and induction of major histocompatibility complex class II mRNA in leishmania-infected macrophages. Proc Natl Acad Sci U S A 1988; 85: 4330–4.
14. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes: evidence that interferon-gamma is the activating lymphokine. J Clin Invest 1983; 72: 1506–10.
15. Murray HW, Spitalny GL, Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol 1985; 134: 1619–22.
16. Hoover DL, Nacy CA, Meltzer MS. Human monocyte activation for cytotoxicity against intercellular Leishmania donovani amastigotes: induction of microbicidal activity by interferon-gamma. Cell Immunol 1985; 94: 500–11.
17. Murray HW, Berman JD, Wright SD. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis 1988; 157: 973–8.
18. Nathan CF, Horowitz CA, de la Harpe J, et al. Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A 1985; 82: 8686–90.
19. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon-γ in patients with lepromatous leprosy. N Engl J Med 1986; 315: 6–15.
20. Murphy PM, Lane HC, Gallin JI, Fauci AS. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-γ. Ann Intern Med 1988; 108: 36–41.
21. Ezekowitz RAB, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988; 319: 146–51.
22. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986; 154: 1003–11.
23. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32: 475–9.
24. Lee SH, Aggarwal BB, Rinderkneckt E, Assisi F, Chiu H. The synergistic anti-proliferative effect of γ interferon and human lymphotoxin. J Immunol 1984; 133: 1083–6.
25. Steeg PS, Moore RN, Johnson HM, Oppenheim JJ. Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med 1982; 156: 1780–93.
26. Gerrard TL, Dyer DR, Zoon KC, zur Nedden D, Siegel JP. Modulation of class I and class II histocompatibility antigens on human T cell lines by IFNγ. J Immunol 1988; 140: 3450–5.
27. Spitalny GL, Havell EA. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage fumoricidal activities. J Exp Med 1984; 159: 1560–5.
28. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984; 160: 1147–69.
29. Nathan C, Yoshida R. Cytokines: interferon-γ. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1988:229–51.
30. Talpaz M, Kantarjian HM, Kurzrock R, Gutterman J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol 1988; 25: 62–73.
31. Kaplan EH, Rosen ST, Norris D, Roenigk H Jr, Saks S, Bunn PA Jr. Phase II trial of recombinant human interferon-gamma in cutaneous T-cell lymphoma. Proc Am Soc Clin Oncol 1988; 7: 226. abstract.
32. Mizel SB. Interleukin 1 and T cell activation. Immunol Rev 1982; 63: 51–72.
33. Durum SK, Schmidt JA, Oppenheim JJ. Interleukin 1: an immunological perspective. Annu Rev Immunol 1985; 3: 263–87.